{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:45:33Z","timestamp":1786221933083,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.07.013","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:18:13Z","timestamp":1786162693000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reducing MRI Use in Organized Prostate Cancer Testing Using Blood-based Biomarkers: The OPT Stockholm3 Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1152-3005","authenticated-orcid":false,"given":"Ugo Giovanni","family":"Falagario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Akre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abbadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Arvendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lottie","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jiborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka Arnsrud","family":"Godtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.07.013_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.07.013_b0010","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening - 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.07.013_b0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/jpm14010084","article-title":"Health policy for prostate cancer early detection in the European Union and the impact of opportunistic screening: PRAISE-U consortium","volume":"14","author":"Beyer","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.euo.2026.07.013_b0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/bju.16211","article-title":"Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge","volume":"133","author":"Albertsen","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.07.013_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071082","article-title":"Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit","volume":"381","author":"Vickers","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.07.013_b0030","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.euf.2022.06.008","article-title":"Designing and implementing a population-based organised prostate cancer testing programme","volume":"8","author":"Alterbeck","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.07.013_b0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","article-title":"Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men","volume":"85","author":"Bratt","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.013_b0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2340\/sju.v60.43809","article-title":"Swedish regional population-based organised prostate cancer testing: why, what and how?","volume":"60","author":"Bratt","year":"2025","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2026.07.013_b0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2017.12.028","article-title":"The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential","volume":"74","author":"Str\u00f6m","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.013_b0050","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.07.013_b0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.eururo.2021.12.021","article-title":"Cost-effectiveness of the Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study","volume":"82","author":"Hao","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.013_b0060","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf062","article-title":"Data resource profile: STHLM0, the Stockholm prostate cancer diagnostics register","volume":"54","author":"Abbadi","year":"2025","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.euo.2026.07.013_b0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12916-018-1019-5","article-title":"The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study","volume":"16","author":"Gnanapragasam","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.euo.2026.07.013_b0070","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.euo.2024.10.016","article-title":"Repeat prostate cancer screening using blood-based risk prediction or prostate-specific antigen in the era of magnetic resonance imaging-guided biopsies: a secondary analysis of the STHLM3-MRI randomized clinical trial","volume":"8","author":"Discacciati","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.07.013_b0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eururo.2023.09.027","article-title":"Multiparametric magnetic resonance imaging in prostate cancer screening at the age of 45 years: results from the first screening round of the PROBASE trial","volume":"85","author":"Boschheidgen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.013_b0080","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.07.013_b0085","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/10408363.2022.2033161","article-title":"Prostate cancer biomarkers: a practical review based on different clinical scenarios","volume":"59","author":"Falagario","year":"2022","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.euo.2026.07.013_b0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.euros.2025.03.006","article-title":"Personalised prostate cancer diagnosis: evaluating biomarker-based approaches to reduce unnecessary magnetic resonance imaging and biopsy procedures","volume":"75","author":"Soeterik","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.07.013_b0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2024.04.037","article-title":"Performance of 4Kscore as a reflex test to prostate-specific antigen in the GOTEBORG-2 prostate cancer screening trial","volume":"86","author":"Josefsson","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.013_b0100","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2026.07.013_b0105","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.euf.2025.06.008","article-title":"Prostate-specific antigen density as a selection tool before magnetic resonance imaging in prostate cancer screening: an analysis from the STHLM3MRI randomized clinical trial","volume":"11","author":"Bj\u00f6rnebo","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.07.013_b0110","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.euo.2025.05.015","article-title":"Prostate cancer testing between screening rounds: evidence from the STHLM3-MRI trial","volume":"8","author":"Skalt","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.07.013_b0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54577","article-title":"Repeated prostate cancer screening using prostate-specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3-MRI randomized clinical trial","volume":"7","author":"Nordstr\u00f6m","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.07.013_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246674","article-title":"The cost-effectiveness of prostate cancer screening using the Stockholm3 test","volume":"16","author":"Karlsson","year":"2021","journal-title":"PLoS One"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:34:32Z","timestamp":1786221272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"alternative-id":["S2588931126002038"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.07.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing MRI Use in Organized Prostate Cancer Testing Using Blood-based Biomarkers: The OPT Stockholm3 Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}